Efficacy and safety of perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for locally advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized phase III trials.
Adding immune checkpoint inhibitors to chemotherapy in advanced gastric cancer improves outcomes in early clinical trials.
This meta-analysis pools data from phase III randomized trials comparing perioperative immunotherapy plus chemotherapy versus chemotherapy alone in locally advanced gastric cancer. The results support adding immune checkpoint inhibitors to the perioperative treatment paradigm.
What the study was
- Study design
- Systematic review and meta-analysis of RCTs
- Population
- Locally advanced gastric/GEJ adenocarcinoma patients
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Frontiers in Oncology
Why it surfaced
High-quality meta-analysis of phase III RCTs in a high-need GI cancer population. Strong study design. Near-term practice implications.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.